


Introduction

Pharmacology and Toxicology Central Nervous System Module Third Year Medical Students Tareq Saleh, MD, PhD Faculty of Medicine The Hashemite University






The Neuron








Action Potential






Action Potential







MakeAGIF.com






The resting membrane potential is established by the K^+ electrochemical gradient of Na⁺ Depolarization occurs mainly due to the influx of **K**⁺ Hyperpolarization occurs mainly due to the efflux of The type of ion channel that accounts for rapid depolarization is Voltage-gated Na⁺ Channels

Action potentials move in one direction. T or F?





The Synapse



Receptor for neurotransmitter Copyright © 2018 Wolters Kluwer • All Rights Reserved





Neurotransmitters

- Endogenous chemicals that enable neurotransmission
- Released by the <u>arrival of action potential</u> (depolarization) at the nerve ending





What Makes a Chemical Substance a Neurotransmitter?

- 1) The chemical must be synthesized in the neuron.
- 2) When the neuron is active, the chemical must be released and produce a response in some target.
- 3) The same response must be obtained when the chemical is experimentally placed on the target.
- 4) A mechanism must exist for removing the chemical from its site of activation after its work is done.





Types of CNS neurotransmitters

Acetylcholine

- Nicotinic and muscarinic receptors

- Amino acids
 - GABA (gamma-aminobutyric acid)
 - GABA_A and GABA_B receptors
 - ✤ Glycine
 - Glycine receptors
 - Glutamate
 - AMPA and NMDA receptors

- Biogenic Amines
 Catecholamines
 Norepinephrine
 - Adrenergic receptors
 - Dopamine:
 - Dopamine receptors
 - Serotonin
 - Serotonin receptors
- Peptides
 - Endogenous opioids
 - Opioids receptors
 - Substance P



Excitatory Neurotransmitters

Acetylcholine







Types of CNS neurotransmitters

Acetylcholine

- Nicotinic and muscarinic receptors

- Amino acids
 - GABA (gamma-aminobutyric acid)
 - GABA_A and GABA_B receptors
 - ✤ Glycine
 - Glycine receptors
 - Glutamate
 - AMPA and NMDA receptors

- Biogenic Amines
 Catecholamines
 Norepinephrine
 - Adrenergic receptors
 - Dopamine:
 - Dopamine receptors
 - Serotonin
 - Serotonin receptors
- Peptides
 - Endogenous opioids
 - Opioids receptors
 - Substance P



Inhibitory Neurotransmitters

GABA (gamma-aminobutyric acid)

✤ Glycine







Excitatory vs Inhibitory

Acetylcholine

- - * Glycine
 - ✤ Glutamate

Biogenic Amines
 Catecholamines
 Norepinephrine

Dopamine

- * Serotonin
- Peptides

 Endogenous opioids




NEUROTRANSMITTER		POSTSYNAPTIC EFFECTS
	Acetylcholine	Excitatory: Involved in arousal, short-term memory, learning and movement.
BIOGENIC AMINES	Norepinephrine	Excitatory: Involved in arousal, wakefulness, mood, and cardiovascular regulation.
	Dopamine	Excitatory: Involved in emotion, reward systems and motor control.
	Serotonin	Excitatory/Inhibitory: Feeding behavior, control of body temperature, modulation of sensory pathways including nociception (stimulation of pain nerve sensors), regulation of mood and emotion, and sleep/wakefulness.
AMINO ACIDS	GABA	Inhibitory: Increases CI [®] flux into the postsynaptic neuron, resulting in hyperpolarization. Mediates the majority of inhibitory postsynaptic potentials.
	Glycine	Inhibitory: Increases CI [®] flux into the postsynaptic neuron, resulting in hyperpolarization.
	Glutamate	Excitatory: Mediates excitatory Na ⁺ influx into the postsynaptic neuron.
NEURO- PEPTIDES	Substance P	Excitatory: Mediates nociception (pain) within the spinal cord.
	Met-enkephalin	Generally inhibitory: Mediates analgesia as well as other central nervous system effects.

sille.

A LANDARE MANAGEMENT

Excitatory Postsynaptic Potentials (EPSP)


- Release of an excitatory NT
- NT binds to its receptor on the postsynaptic neuron
- Influx of Na⁺ or Ca⁺⁺ → depolarization





Inhibitory Postsynaptic Potentials (IPSP)

- Release of an inhibitory NT
- NT binds to its receptor on the postsynaptic neuron
- Influx of Cl⁻ or efflux of K⁺ → hyperpolarization







The predominant excitatory neurotransmitter in the brain is Glutamate


The predominant inhibitory neurotransmitter in the brain is **Glycine**






Receptors


- Ionotropic
 - e.g., Ligand-gated ion channels
- Metabotropic
 - e.g., G-protein coupled receptors (GPCRs)
 - May or may NOT lead to ion channel opening.











А







Types of CNS Receptors

• Excitatory:


- Ionotropic receptors:
 - Nicotinic acetylcholine receptors
- Metabotropic receptors:
 - Muscarinic acetylcholine receptors
 - Dopamine (D₁) receptors

• Inhibitory:

- Ionotropic receptors:
 - GABA_A receptors
- Metabotropic receptors:
 - Opioid receptors
 - GABA_B receptors




Neurotransmitter Cycle










Inhibit action potential presynaptically:


 Local Anesthetics General Anesthetics

📕 Wolters Kluwer




Inhibit NT Synthesis:

•Tyrosine hydroxylase (catecholamines)










Interference with storage:

•VMAT is inhibited by reserpine •Consequences?






Metabolism:

•COMT and MAO

 Antiparkinsonian •Antidepressants






Release of NT:

•CNS stimulants

18 Wolters Kluwer • All Rights Reserved






NT action on receptor:

- Agonist
- Antagonist
- •Biased agonist
- Allosteric modulators















Allosteric modulator



Negsättive Allostteniic modulator








Intracellular effects:

 cAMP degradation inhibitors


🔜 Wolters Kluwer



Degradation of NT:

 Acetylcholine esterase inhibitors Alzheimer's Disease





NT reuptake:

•Antidepressants



18 Wolters Kluwer • All Rights Reserved



GABA_A receptors are example of:

- a) Excitatory ionotropic receptors.
- b) Inhibitory metabotropic receptors.
- voltage-gated channels
- I) Inhibitory ionotropic receptors.
- Excitatory metabotropic receptors

Which ion is allowed inside the cell upon GABA_A receptor stimulation?





You are the leading physician-scientist of the research and development team in a pharmaceutical company. Your team is working on the development of novel therapies to treat Parkinson's disease. Parkinson's disease is characterized by decreased dopaminergic stimulation in the brain. In your research proposal, you include several strategies to improve parkinsonism by targeting different biochemical processes of dopamine signaling. Which of the following mechanisms will NOT be included in your proposal?

- a) Inhibition of the vesicular monoamine transporter 2 (VMAT-2).
- b) Inhibition of catechol-O-methyltransferase (COMT)
- c) Designing more efficacious D₂ receptor agonists.
- d) Designing novel therapies that promote the regeneration of substantia nigra dopaminergic neurons.





- Thank you
- Questions?

